ClinicalTrials.gg
Active, not recruitingNCT05338775TRIMM-3Updated Nov 3, 2026

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of Talquetamab and Teclistamab in Relapsed/ Refractory Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 19 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Updated Sep 25, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing talquetamab in Multiple Myeloma — 20 open to participants now, 27 under way, 6 of them phase 3. talquetamab · Multiple Myeloma.

Enrollment
13th of 30
74 · median 50
Started
2022
with 4 others
Phase 1
6 of 30
4 open now
Primary completion
2025-05
later than 1 of 26 live
Registered
4th of 30
by date
Lead sponsor
10 of 30
Janssen Research & Development, LLC

Among the 30 studies testing talquetamab in Multiple Myeloma, this one is the 13th largest by enrollment, is one of 5 that started in 2022, is one of 6 in phase 1, reaches primary completion later than 1 of the 26 other live ones, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

20 of the 30 studies testing talquetamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About talquetamab

talquetamab: first FDA approval 2023 (TALVEY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing talquetamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.

03

Conditions studied

  • Relapsed/ Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
  • Participants with disease that are not a candidate for available therapy with established clinical benefit
  • Have at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL); b) Urine M-protein level >= 200 milligrams (mg) per 24 hours; c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligrams/deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
  • Have an (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior antitumor therapy within 21 days prior to the first dose of study treatment (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene -modified adoptive cell therapy or stem cell transplant within 3 months)
  • Prior therapy with inhibitors, allogeneic stem cell transplant or solid organ transplant
  • Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis
  • Active Central Nervous System (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
  • Live, attenuated vaccine within 4 weeks before the first dose of study treatment
  • Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (\<=) 1 (except alopecia [any grade] or peripheral neuropathy to Grade \<= 2)
  • Received a cumulative dose of equivalent to >= 140 milligrams (mg) of prednisone within the 14-day period before the start of study treatment administration
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly.

    Drug: Talquetamab · Drug: Teclistamab · Drug: PD-1 Inhibitor

  • Experimental
    Part 2: Dose Expansion

    Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1.

    Drug: Talquetamab · Drug: Teclistamab · Drug: PD-1 Inhibitor

Interventions

  • Talquetamab will be administered as a subcutaneous (SC) injection.

  • Teclistamab will be administered as a SC injection.

  • The PD-1 inhibitor will be administered as an intravenous injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 2 years 5 months

  2. Number of Participants with Adverse Events (AEs) by Severity

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.

    Time frame: Up to 2 years 5 months

  3. Number of Participants with Abnormalities in Clinical Laboratory Assessments

    Number of participants with abnormalities in clinical laboratory assessments (serum chemistry and hematology) will be reported.

    Time frame: Up to 2 years 5 months

  4. Number of Participants with Dose-Limiting Toxicity (DLTs)

    The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

    Time frame: Up to 2 years 5 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve partial response (PR) or better according to the International Myeloma Working Group (IMWG) 2016 criteria.

    Time frame: Up to 2 years 5 months

  2. Very Good Partial Response (VGPR) or Better Response Rate

    VGPR or better response rate is defined as the percentage of participants who achieve a VGPR or better response (stringent complete response \[sCR\]+ complete response \[CR\]+VGPR) according to the IMWG 2016 criteria.

    Time frame: Up to 2 years 5 months

  3. Complete Response (CR) or Better Response Rate

    CR or better response rate is defined as the percentage of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria.

    Time frame: Up to 2 years 5 months

  4. Stringent Complete Response (sCR) Rate

    sCR rate is defined as the percentage of participants who achieve an sCR according to the IMWG 2016 criteria.

    Time frame: Up to 2 years 5 months

  5. Duration of Response

    Duration of response is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG 2016 criteria or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years 5 months

  6. Time to Response

    Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better.

    Time frame: Up to 2 years 5 months

  7. Serum Concentrations of Talquetamab

    Serum samples will be analyzed to determine concentrations of Talquetamab using validated, specific, and sensitive immunoassay methods.

    Time frame: Up to 2 years 5 months

  8. Serum Concentrations of Teclistamab

    Serum samples will be analyzed to determine concentrations of Teclistamab using validated, specific, and sensitive immunoassay methods.

    Time frame: Up to 2 years 5 months

  9. Serum Concentrations of PD-1 Inhibitor

    Serum samples will be analyzed to determine concentrations of PD-1 inhibitor using validated, specific, and sensitive immunoassay methods.

    Time frame: Up to 2 years 5 months

  10. Number of Participants with Anti-Talquetamab Antibodies

    Number of participants with anti-talquetamab antibodies will be reported.

    Time frame: Up to 2 years 5 months

  11. Number of Participants with Anti-Teclistamab Antibodies

    Number of participants with anti-teclistamab antibodies will be reported.

    Time frame: Up to 2 years 5 months

  12. Number of Participants with Anti-PD-1 Inhibitor Antibodies

    Number of participants with anti-PD-1 inhibitor antibodies will be reported.

    Time frame: Up to 2 years 5 months

07

Study locations

19 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2025, 35 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 35 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Dec 2027, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 21, 2022
StartActual
May 25, 2022
Primary completionActual
May 22, 2025
CompletionEst.
Dec 31, 2027was May 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
May 3, 2027→Dec 31, 2027
Sep 25, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    Study completion May 3, 2027→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05338775
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
May 25, 2022
Primary completion
May 22, 2025
Completion
Dec 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research and Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talquetamab · Teclistamab · Immune checkpoint inhibitors

Start the discussion